US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% NVDA $233.95 ▲+0.00% SNDK $1,719.99 ▲+0.00% SPCX $158.96 ▲+0.00% SDEV $7.48 ▲+0.00% TSLA $370.59 ▲+0.00% AMD $633.91 ▲+0.00%
FinancialContent

Articles published by Esperion Therapeutics, Inc.

< Previous 1 2 3 4 5 Next >
News headline image
Esperion Therapeutics Offers Short-Term Option for Diuretic Management Before Escalation to IV for Patients With Heart Failure
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
News headline image
Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
News headline image
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
News headline image
Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
News headline image
Esperion to be Acquired by ARCHIMED
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
News headline image
Esperion to Report First Quarter 2026 Financial Results on May 7
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
News headline image
Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
News headline image
Esperion to Participate in 25th Annual Needham Virtual Healthcare Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
News headline image
Esperion Showcases New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) at the American College of Cardiology’s Annual Scientific Session 2026
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
News headline image
Esperion to Present Two New Analyses from CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific Session
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
News headline image
Esperion’s Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
News headline image
Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
News headline image
Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
News headline image
Esperion to Report Fourth Quarter and Full Year 2025 Financial Results on March 10
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
News headline image
Esperion to Participate in The 2026 Citizens Life Sciences Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
News headline image
Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
News headline image
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
News headline image
Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
News headline image
Esperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
News headline image
Esperion’s Bempedoic Acid Receives Recommendation in 2025 ACC Scientific Statement on Management of Peripheral Artery Disease in Adults With Diabetes
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
News headline image
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
News headline image
Esperion Partner Otsuka Launches NEXLETOL® in Japan for the Treatment of Hypercholesterolemia
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
News headline image
Esperion to Participate in Piper Sandler 37th Annual Healthcare Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
News headline image
Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR TSX:HLS
News headline image
Esperion Announces New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) in Oral and Poster Presentations at the AHA Scientific Sessions 2025
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
News headline image
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
News headline image
Esperion Reports Third Quarter 2025 Financial Results and Provides Business Update
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
News headline image
Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
News headline image
Esperion to Participate in Jefferies Global Healthcare Conference - London
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
News headline image
Esperion to Host Virtual Investor Key Opinion Leader Event Highlighting Significant Unmet Need in Statin Intolerance on Tuesday, November 11, 2025, at 2:00 p.m. ET.
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Tickers ESPR
< Previous 1 2 3 4 5 Next >